IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome

Neurology

Volumn 52, Issue 9, 1999, Pages 1833-1838

  Sharief, M K ^a   Ingram, D A ^b   Swash, M ^b   Thompson, E J ^c  

^a GUY S HOSPITAL   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HUMAN IMMUNOGLOBULIN; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN;

ADULT; ARTICLE; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG MECHANISM; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INTRAVENOUS DRUG ADMINISTRATION; NEGATIVE FEEDBACK; PATHOGENESIS; PRIORITY JOURNAL; BLOOD; FOLLOW UP; INFLAMMATION; PLASMAPHERESIS; POLYRADICULONEUROPATHY;

ADULT; CYTOKINES; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; PLASMA EXCHANGE; POLYRADICULONEUROPATHY;

EID: 0032588204     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.9.1833     Document Type: Article

References (40)

1. Hughes RAC, Swan AV, Cornblath DR, et al. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-230.
2. Kaveri SV, Mouthon L, Kazatchkine MD. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J Neurol Neurosurg Psychiatry 1994; 57(suppl):6-8.
3. Stangel M, Hartung HP, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 1998;153:203-214.
4. Pashov A, Bellon B, Kaveri SV, Kazatchkine MD. A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins. Mult Scler 1997;3:153-156.
5. Tenser RB, Hay KA, Aberg JA. Immunoglobulin G immunosuppression of multiple sclerosis: suppression of all three lymphocyte subsets. Arch Neurol 1993;50:417-420.
6. Kondo N, Ozawa T, Mushiake K, et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991;11:152-158.
7. Berchtold P, Dale GL, Tani P, McMillan R. Inhibition of auto-antibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous immunoglobulin. Blood 1989;74:2414-2419.
8. Basta M, Dalakas MC. High dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
9. Achiron A, Margalit R, Hershkoviz R, et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease: upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest 1994;93:600-605.
10. Sharief MK, McLean B, Thompson EJ. Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol 1993;33:591-596.
11. Créange A, Belec L, Clair B, Raphael J, Gherardi RK. Circulating tumor necrosis factor-α and soluble TNF-α receptors in patients with Guillain-Barré syndrome. J Neuroimmunol 1996;68:95-99.
12. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472.
13. Wang P, Wu PW, Siegel MI, Egan RW, Billah MM. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 1994;153:811-816.
14. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231-240.
15. Gerard C, Bruyns C, Marchant A, et al. Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177(suppl 1) :547-550.
16. Brockhaus M, Schoenfelf HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990;87:3127-3131.
17. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27(suppl 1):S21-S24.
18. Brown WF, Feasby TE, Hahn AF. Electrophysiological changes in the acute axonal form of Guillain-Barré syndrome. Muscle Nerve 1993;16:200-205.
19. Sharief MK, Ingram DA, Swash M. Circulating tumor necrosis factor-α correlates with electrodiagnostic abnormalities in Guillain-Barré syndrome. Ann Neurol 1997;42:68-73.
20. Hughes RAC, Newson-Davis J, Perkin G. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
21. Lacroix-Desmazes S, Mouthon L, Spalter SH, Kaveri S, Kazatchkine MD. Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol 1996;14(suppl 15):S9-S15.
22. Ling ZD, Yeoh E, Webb BT, Farrell K, Doucette J, Matheson DS. Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo. J Clin Immunol 1993;13:302-309.
23. Suzuki H, Uemura S, Tone S, et al. Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1beta by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr 1996;155:291-296.
24. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994;73:180-186.
25. Toyoda M, Zhang X, Petrosian A, Galera OA, Wang SJ, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994;14: 178-189.
26. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-2143.
27. Ruiz de Souza V, Carreno MP, Kaveri SV, et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IVIg (intravenous immunoglobulin). Eur J Immunol 1995;25:1267-1273.
28. van der Meche FG, Visser LH, Jacobs BC, Endtz HP, Meulstee J, van Doom PA. Guillain-Barre syndrome: multifactorial mechanisms versus defined subgroups. J Infect Dis 1997; 176(suppl 2):S99-S102.
29. Nachbaur D, Herold M, Eibl B, et al. A comparison study of the in vitro immunomodulators activity of human intact immunoglobulin (7S IVIg), F(ab′)2 fragments (5S IVIg) and Fc fragments: evidence for post-transcriptional IL-2 modulation. Immunology 1997;90:212-218.
30. Modiano JF, Amran D, Lack G, et al. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobulin. Clin Immunol Immunopathol 1997;83:77-85.
31. Toungouz M, Denys C, Dupont E. Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins. Transplant 1996;62:1292-1296.
32. Sindern E, Schweppe K, Ossege LM, Malin JP. Potential role of transforming growth factor-beta1 in terminating the immune response in patients with Guillain-Barre syndrome. J Neurol 1996;243:264-268.
33. Creange A, Belec L, Clair B, Degos J-D, Raphael J-C, Gherardi RK. Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barre syndrome: decreased concentrations in the early course and increase with motor function. J Neurol Neurosurg Psychiatry 1998;64:162-165.
34. de Waal MR, Bennett B, Fidgor C, De Vries JE. Interleukin-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
35. Eliaz R, Wallach D, Kost J. Long-term protection against the effects of tumour necrosis factor by controlled delivery of soluble p55 TNF receptor. Cytokine 1996;8:482-487.
36. Busund R, Lindsetmo RO, Rasmussen LT, Rokke O, Rekvig OP, Revhaug A. Tumor necrosis factor and interleukin 1 appearance in experimental gram-negative septic shock: the effects of plasma exchange with albumin and plasma infusion. Arch Surg 1991;126:591-597.
37. Rokke O, Rolf S, Revhaug A, Rekvig OP. Plasma exchange, but not extracorporal recirculation nor removal of white blood cells, depresses plasma levels of IL-1 during severe gramnegative septicemia. Transfus Sci 1993;14:173-182.
38. Wang MJ, Chiu IS, Hsu CM, et al. Efficacy of ultrafiltration in removing inflammatory mediators during pediatric cardiac operations. Ann Thorac Surg 1996;61:651-656.
39. Saatvedt K, Lindberg H, Geiran OR, et al. Ultrafiltration after cardiopulmonary bypass in children: effects on hemodynamics, cytokines and complement. Cardiovasc Res 1996;31: 596-602.
40. Redford EJ, Hall SM, Smith KJ. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 1995;118:869-878.